{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:50:04Z","timestamp":1792194604960,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["RO1CA201458"],"award-info":[{"award-number":["RO1CA201458"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["RO1CA201458"],"award-info":[{"award-number":["RO1CA201458"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA13330"],"award-info":[{"award-number":["P30CA13330"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-07662-3","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T08:08:52Z","timestamp":1740211732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Distinct outcomes from targeted perturbations of the multi-subunit SCFSkp2 E3 ubiquitin ligase in blocking Trp53\/Rb1-null prostate tumorigenesis"],"prefix":"10.1038","volume":"8","author":[{"given":"Yingjiao","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumen","family":"Karan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Locker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-6958","authenticated-orcid":false,"given":"Juan Pablo","family":"Maianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-2277","authenticated-orcid":false,"given":"Hongling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0669-9292","authenticated-orcid":false,"given":"Edward L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"7662_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645\u2013651 (2018).","journal-title":"Nat. Genet."},{"key":"7662_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-18-2068","volume":"25","author":"D Nava Rodrigues","year":"2019","unstructured":"Nava Rodrigues, D. et al. RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer. Clin. Cancer Res. 25, 687\u2013697 (2019).","journal-title":"Clin. Cancer Res."},{"key":"7662_CR3","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo, J. et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Invest. 130, 1743\u20131751 (2020).","journal-title":"J. Clin. Invest."},{"key":"7662_CR4","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.1158\/0008-5472.CAN-06-0486","volume":"66","author":"Z Zhou","year":"2006","unstructured":"Zhou, Z. et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 66, 7889\u20137898 (2006).","journal-title":"Cancer Res."},{"key":"7662_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ccr.2013.09.021","volume":"24","author":"H Zhao","year":"2013","unstructured":"Zhao, H. et al. Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell 24, 645\u2013659 (2013).","journal-title":"Cancer Cell"},{"key":"7662_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107669","volume":"31","author":"M. D Nyquist","year":"2020","unstructured":"Nyquist, M. D. et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 31, 107669 (2020).","journal-title":"Cell Rep."},{"key":"7662_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84\u201388 (2017).","journal-title":"Science"},{"key":"7662_CR8","first-page":"549","volume":"14","author":"J. K Sabari","year":"2017","unstructured":"Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T. & Rudin, C. M. Unravelling the biology of SCLC: implications for therapy. Nat. Rev. Cancer 14, 549\u2013561 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"7662_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrc2713","volume":"9","author":"E. A Musgrove","year":"2009","unstructured":"Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631\u2013643 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"7662_CR10","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41388-024-02942-4","volume":"43","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma. Oncogene 43, 962\u2013975 (2024).","journal-title":"Oncogene"},{"key":"7662_CR11","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1101\/gad.282145.116","volume":"30","author":"N. J Dyson","year":"2016","unstructured":"Dyson, N. J. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 30, 1492\u20131502 (2016).","journal-title":"Genes Dev."},{"key":"7662_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molcel.2004.09.029","volume":"16","author":"P Ji","year":"2004","unstructured":"Ji, P. et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol. Cell 16, 47\u201358 (2004).","journal-title":"Mol. Cell"},{"key":"7662_CR13","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/sj.onc.1209286","volume":"25","author":"L Zhang","year":"2006","unstructured":"Zhang, L. & Wang, C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 25, 2615\u20132627 (2006).","journal-title":"Oncogene"},{"key":"7662_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4463","volume":"5","author":"Z Lu","year":"2014","unstructured":"Lu, Z. et al. Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity. Nat. Commun. 5, 3463 (2014).","journal-title":"Nat. Commun."},{"key":"7662_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nrd4432","volume":"13","author":"J. R Skaar","year":"2014","unstructured":"Skaar, J. R., Pagan, J. K. & Pagano, M. SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 13, 889\u2013903 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"7662_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ng.498","volume":"42","author":"H Wang","year":"2010","unstructured":"Wang, H. et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+\/- mice. Nat. Genet. 42, 83\u201388 (2010).","journal-title":"Nat. Genet."},{"key":"7662_CR17","doi-asserted-by":"publisher","first-page":"10201","DOI":"10.1074\/jbc.M116.718049","volume":"291","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. Deletions of retinoblastoma 1 (Rb1) and its repressing target S phase kinase-associated protein 2 (Skp2) are synthetic lethal in mouse embryogenesis. J. Biol. Chem. 291, 10201\u201310209 (2016).","journal-title":"J. Biol. Chem."},{"key":"7662_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41416-022-01898-0","volume":"127","author":"P Gupta","year":"2022","unstructured":"Gupta, P., Zhou, H., Hoang, B. & Schwartz, E. L. Targeting the untargetable: RB1-deficient tumors are vulnerable to Skp2 ubiquitin ligase inhibition. Br. J. Cancer 127, 969\u2013975 (2022).","journal-title":"Br. J. Cancer"},{"key":"7662_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/359295a0","volume":"359","author":"T Jacks","year":"1992","unstructured":"Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295\u2013300 (1992).","journal-title":"Nature"},{"key":"7662_CR20","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1038\/onc.2017.64","volume":"36","author":"D Ruan","year":"2017","unstructured":"Ruan, D. et al. Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist. Oncogene 36, 4299\u20134310 (2017).","journal-title":"Oncogene"},{"key":"7662_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/onc.2016.175","volume":"36","author":"H Zhao","year":"2017","unstructured":"Zhao, H. et al. p27T187A knockin identifies Skp2\/Cks1 pocket inhibitors for advanced prostate cancer. Oncogene 36, 60\u201370 (2017).","journal-title":"Oncogene"},{"key":"7662_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nature08815","volume":"464","author":"H. K Lin","year":"2010","unstructured":"Lin, H. K. et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374\u2013379 (2010).","journal-title":"Nature"},{"key":"7662_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrc2396","volume":"8","author":"D Frecas","year":"2008","unstructured":"Frecas, D. & Pagano, M. Deregulated proteolysis by the F-box proteins Skp2 and \u00df-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 8, 438\u2013449 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"7662_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/12013","volume":"1","author":"A. C Carrano","year":"1999","unstructured":"Carrano, A. C., Eytan, E., Hershko, A. & Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1, 193\u2013199 (1999).","journal-title":"Nat. Cell Biol."},{"key":"7662_CR25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1101\/gad.11.11.1464","volume":"11","author":"R. J Sheaff","year":"1997","unstructured":"Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M. & Clurman, B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11, 1464\u20131478 (1997).","journal-title":"Genes Dev."},{"key":"7662_CR26","doi-asserted-by":"publisher","first-page":"14009","DOI":"10.1073\/pnas.0606316103","volume":"103","author":"I Timmerbeul","year":"2006","unstructured":"Timmerbeul, I, et al. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc. Natl. Acad. Sci. USA 103, 14009\u201314014 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7662_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/35095083","volume":"413","author":"N. P Malek","year":"2001","unstructured":"Malek, N. P, et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 413, 323\u2013327 (2001).","journal-title":"Nature"},{"key":"7662_CR28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1039\/C8MD00140E","volume":"9","author":"L Lough","year":"2018","unstructured":"Lough, L. et al. Chemical probes of Skp2-mediated p27 ubiquitylation and degradation. MedChemComm 9, 1093\u20131104 (2018).","journal-title":"MedChemComm"},{"key":"7662_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/35060126","volume":"3","author":"D Ganoth","year":"2001","unstructured":"Ganoth, D, et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat. Cell Biol. 3, 321\u2013324 (2001).","journal-title":"Nat. Cell Biol."},{"key":"7662_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1097-2765(01)00210-6","volume":"7","author":"C Spruck","year":"2001","unstructured":"Spruck, C, et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol. Cell 7, 639\u2013650 (2001).","journal-title":"Mol. Cell"},{"key":"7662_CR31","doi-asserted-by":"crossref","unstructured":"Hao, B. et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol. Cell 20, 9\u201319 (2005).","DOI":"10.1016\/j.molcel.2005.09.003"},{"key":"7662_CR32","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1128\/MCB.06771-11","volume":"32","author":"A Hoellein","year":"2012","unstructured":"Hoellein, A, et al. Cks1 promotion of S phase entry and proliferation is independent of p27Kip1 suppression. Mol. Cell Biol. 32, 2416\u20132427 (2012).","journal-title":"Mol. Cell Biol."},{"key":"7662_CR33","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1128\/MCB.23.15.5165-5173.2003","volume":"23","author":"J Garriga","year":"2003","unstructured":"Garriga, J. et al. CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol. Cell Biol. 23, 5165\u20135173 (2003).","journal-title":"Mol. Cell Biol."},{"key":"7662_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molcel.2007.02.022","volume":"26","author":"B Hao","year":"2007","unstructured":"Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W. & Pavletich, N. P. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131\u2013143 (2007).","journal-title":"Mol. Cell"},{"key":"7662_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/0092-8674(95)90271-6","volume":"22","author":"H Zhang","year":"1995","unstructured":"Zhang, H., Kobayashi, R., Galaktionov, K. & Beach, D. P19skpl and P45skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 22, 915\u2013925 (1995).","journal-title":"Cell"},{"key":"7662_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-37609-9","volume":"13","author":"R. J Rowland","year":"2023","unstructured":"Rowland, R. J. et al. Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-P27KIP1. Sci. Rep. 13, 10718 (2023).","journal-title":"Sci. Rep."},{"key":"7662_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41586-020-2000-y","volume":"578","author":"K Baek","year":"2020","unstructured":"Baek, K. et al. NEDD8 nucleates a multivalent cullin\u2013RING\u2013UBE2D ubiquitin ligation assembly. Nature 578, 461\u2013466 (2020).","journal-title":"Nature"},{"key":"7662_CR38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-03197-9","volume":"590","author":"D Horn-Ghetko","year":"2021","unstructured":"Horn-Ghetko, D. et al. Ubiquitin ligation to F-box protein targets by SCF\u2013RBR E3\u2013E3 super-assembly. Nature 590, 671\u2013676 (2021).","journal-title":"Nature"},{"key":"7662_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/376313a0","volume":"376","author":"P. D Jeffrey","year":"1995","unstructured":"Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313\u2013320 (1995).","journal-title":"Nature"},{"key":"7662_CR40","doi-asserted-by":"publisher","first-page":"10453","DOI":"10.1073\/pnas.95.18.10453","volume":"95","author":"B. A Schulman","year":"1998","unstructured":"Schulman, B. A., Lindstrom, D. L. & Harlow, E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc. Natl. Acad. Sci. USA 95, 10453\u201310458 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7662_CR41","doi-asserted-by":"publisher","first-page":"42233","DOI":"10.1074\/jbc.M205254200","volume":"277","author":"D Sitry","year":"2002","unstructured":"Sitry, D. et al. Three different binding sites of Cks1 are required for p27-ubiquitin ligation. J. Biol. Chem. 277, 42233\u201342240 (2002).","journal-title":"J. Biol. Chem."},{"key":"7662_CR42","doi-asserted-by":"publisher","first-page":"25752","DOI":"10.1074\/jbc.M301774200","volume":"278","author":"G Bornstein","year":"2003","unstructured":"Bornstein, G, et al. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 278, 25752\u201325757 (2003).","journal-title":"J. Biol. Chem."},{"key":"7662_CR43","doi-asserted-by":"publisher","first-page":"10231","DOI":"10.1073\/pnas.1831009100","volume":"100","author":"T Kamura","year":"2003","unstructured":"Kamura, T, et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc. Natl. Acad. Sci. USA 100, 10231\u201310236 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7662_CR44","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/emboj\/19.9.2069","volume":"19","author":"K Nakayama","year":"2000","unstructured":"Nakayama, K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19, 2069\u20132081 (2000).","journal-title":"EMBO J."},{"key":"7662_CR45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nature02330","volume":"428","author":"T Bashir","year":"2004","unstructured":"Bashir, T, Dorrello, N. V, Amador, V, Guardavaccaro, D & Pagano, M Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC\/C(Cdh1) ubiquitin ligase. Nature 428, 190\u2013193 (2004).","journal-title":"Nature"},{"key":"7662_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature02381","volume":"428","author":"W Wei","year":"2004","unstructured":"Wei, W, et al. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428, 194\u2013198 (2004).","journal-title":"Nature"},{"key":"7662_CR47","doi-asserted-by":"publisher","first-page":"24058","DOI":"10.1074\/jbc.M603105200","volume":"281","author":"P Ji","year":"2006","unstructured":"Ji, P, et al. Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1. J. Biol. Chem. 281, 24058\u201324069 (2006).","journal-title":"J. Biol. Chem."},{"key":"7662_CR48","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.str.2021.04.011","volume":"29","author":"S Kelso","year":"2021","unstructured":"Kelso, S. et al. Bipartite binding of the N terminus of Skp2 to cyclin A. Structure 29, 975\u2013988 (2021).","journal-title":"Structure"},{"key":"7662_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2020.166795","volume":"433","author":"M Salamina","year":"2021","unstructured":"Salamina, M. et al. Discriminative SKP2 interactions with CDK-cyclin complexes support a cyclin A-specific role in p27KIP1 degradation. J. Mol. Biol. 433, 166795 (2021).","journal-title":"J. Mol. Biol."},{"key":"7662_CR50","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2174\/0929867323666160510122624","volume":"23","author":"Y Lee","year":"2016","unstructured":"Lee, Y. & Lim, H. S. Skp2 inhibitors: novel anticancer strategies. Curr. Med. Chem. 23, 2363\u20132379 (2016).","journal-title":"Curr. Med. Chem."},{"key":"7662_CR51","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.neuron.2004.06.004","volume":"42","author":"N Balthasar","year":"2004","unstructured":"Balthasar, N. et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 42, 983\u2013991 (2004).","journal-title":"Neuron"},{"key":"7662_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","volume":"101","author":"X Wu","year":"2001","unstructured":"Wu, X, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61\u201369 (2001).","journal-title":"Mech. Dev."},{"key":"7662_CR53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature01764","volume":"424","author":"J Sage","year":"2003","unstructured":"Sage, J, Miller, A. L, P\u00e9rez-Mancera, P. A, Wysocki, J. M & Jacks, T Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424, 223\u2013228 (2003).","journal-title":"Nature"},{"key":"7662_CR54","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ng747","volume":"29","author":"J Jonkers","year":"2001","unstructured":"Jonkers, J, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418\u2013425 (2001).","journal-title":"Nat. Genet."},{"key":"7662_CR55","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0092-8674(00)81239-8","volume":"85","author":"M. L Fero","year":"1996","unstructured":"Fero, M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85, 733\u2013744 (1996).","journal-title":"Cell"},{"key":"7662_CR56","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","volume":"153","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering. Cell 153, 910\u2013918 (2013).","journal-title":"Cell"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07662-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07662-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07662-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T08:08:58Z","timestamp":1740211738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07662-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7662"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07662-3","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"18 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: E.S. is a consultant for Sandoz Pharmaceuticals. J.P.M. is a co-founder of Exo Therapeutics, a company focused on substrate-binding sites. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}